What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis shows CAR T-cell therapy improves treatment response in B-cell lymphomas, suggesting long-term survival remains uncertain.

Overall survival rates were significantly lower for CAR T-cell therapy compared to standard of care, indicating potential limitations in survival outcomes.
The analysis included seven studies that evaluated CAR T-cell therapy versus conventional treatments in B-cell lymphomas.
Randomized controlled trials and observational studies were reviewed to assess safety and efficacy across various treatments.
Adverse events were similar between treatments, highlighting safety considerations for CAR T-cell therapy in clinical use.

Jehangir et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis shows CAR T-cell therapy improves treatment response in B-cell lymphomas, suggesting long-term survival remains uncertain.

Overall survival rates were significantly lower for CAR T-cell therapy compared to standard of care, indicating potential limitations in survival outcomes.
The analysis included seven studies that evaluated CAR T-cell therapy versus conventional treatments in B-cell lymphomas.
Randomized controlled trials and observational studies were reviewed to assess safety and efficacy across various treatments.
Adverse events were similar between treatments, highlighting safety considerations for CAR T-cell therapy in clinical use.

Jehangir et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark